Stem Genomics Announces Partnership with Pluristyx, Leading One-Stop-Shop Solution Provider for High-Quality Cell-Based Therapies.
Pluristyx, Inc. and Stem
Genomics SAS today announce the closing of an equity investment and strategic partnership in Stem Genomics. Through the partnership, the companies will offer a unified pathway to allow customers to evaluate the genomic stability of Pluristyx’s pluripotent...
Pluristyx and the Advanced Regenerative Manufacturing Institute to Commercialize Clinical-Grade Stem Cells
Pluristyx, Inc. today announced an agreement with the
Advanced Regenerative Manufacturing Institute | BioFabUSA to manufacture and
commercialize Pluristyx’s clinical-grade reprogrammed induced Pluripotent Stem Cells (iPSCs).
This collaboration will make it possible to accelerate the scalable, consistent, and cost-effective
manufacturing of stem cell derived...
Pluristyx/panCELLa Become Industry Resource Partner with the California Institute for Regenerative Medicine
The partnership will improve access to clinical-grade genetically-modified induced pluripotent stem cells June 12, 2023 – Seattle – Pluristyx and panCELLa, a merged biotechnology company with offices in Seattle, WA and Toronto, Ontario, CA, are excited to announce their acceptance...